Cargando…

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haggenburg, Sabine, Hofsink, Quincy, Rutten, Caroline E., Nijhof, Inger S., Hazenberg, Mette D., Goorhuis, Abraham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674560/ https://www.ncbi.nlm.nih.gov/pubmed/36805887 http://dx.doi.org/10.1053/j.seminhematol.2022.11.001

Ejemplares similares

P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
por: Pothast, Cilia R., et al.
Publicado: (2022)

P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL
por: Campanella, Alessandro, et al.
Publicado: (2023)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
por: Hofsink, Quincy, et al.
Publicado: (2023)

Immunogenicity of a 5‐dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation
por: Haggenburg, Sabine, et al.
Publicado: (2021)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
por: Huygens, Sammy, et al.
Publicado: (2022)

P1570: SARS-COV-2 HUMORAL AND CELLULAR VACCINATION RESPONSE IN PATIENTS WITH LYMPHOID HAEMATOLOGICAL MALIGNANCIES
por: Boerenkamp, L. S., et al.
Publicado: (2022)

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
por: Ni, Bin, et al.
Publicado: (2022)

Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients
por: Mohanraj, Dinesh, et al.
Publicado: (2022)

Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
por: Ikeda, Daisuke, et al.
Publicado: (2022)

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
por: Mairhofer, Mario, et al.
Publicado: (2021)

Humoral and Cellular Immune Response to Sars-Cov-2 Vaccination in Patients with Chronic GVHD
por: Manjappa, Shivaprasad, et al.
Publicado: (2022)

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
por: Konishi, Yoshinobu, et al.
Publicado: (2022)

Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
por: Taefehshokr, Nima, et al.
Publicado: (2020)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination
por: Hollstein, Moritz M., et al.
Publicado: (2022)

Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
por: Duran-Struuck, Raimon, et al.
Publicado: (2019)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
por: Mohamed, Sara, et al.
Publicado: (2023)

SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis population
por: Anft, Moritz, et al.
Publicado: (2021)

Fusariosis in patients with hematological malignancies: Two case reports
por: Raymakers, Jord W., et al.
Publicado: (2023)

Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments
por: Pfannes, Roald, et al.
Publicado: (2023)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
por: Re, Daniel, et al.
Publicado: (2022)

Vaccination Against Sars-Cov-2 Induces Robust Humoral Immune Response in Patients with Previous Hematologic Stem Cell Transplantation
por: Roldan, Elisa, et al.
Publicado: (2022)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

SARS-CoV-2 vaccination for patients with inflammatory bowel disease
por: Garrido, Hannah M Garcia, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients
por: De Vriese, An S., et al.
Publicado: (2022)

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
por: Oyaert, Matthijs, et al.
Publicado: (2022)

Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients
por: Furian, Lucrezia, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients
por: Kwiatkowska, Ewa, et al.
Publicado: (2022)

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection
por: Pušnik, Jernej, et al.
Publicado: (2023)

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3jm8rl2i35tqolqthnd1thtgja